ADS-024 is under clinical development by Adiso Therapeutics and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADS-024’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ADS-024 overview

ART-24 (ADS-024) is under development for the treatment of Parkinson's disease, mild-to-moderate ulcerative colitis and for the prevention of Clostridium difficile infection recurrence. The therapeutic candidate is an oral single strain live biotherapeutic product (SS-LBP).

Adiso Therapeutics overview

Adiso Therapeutics is a clinical-stage biopharmaceutical startup focused on treating patients with chronic inflammatory illnesses. The company is headquartered in United States.

For a complete picture of ADS-024’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.